Cedivac-FMD; Duration of Immunity in cattle, sheep and pigs. 2004, 8203 AA Lelystad, The Netherlands * Corresponding Author

Similar documents
Regulation of FMD vaccines within the European Union

Mass vaccination, immunity and coverage: Modelling population protection against FMD in Turkish cattle. Theo Knight-Jones Epidemiologist, ILRI

Longevity of the antibody response in pigs and sheep following a single administration of high potency emergency FMD vaccines

FAO Collaborative Study Phase XVII: Standardisation of FMD Antibody Detection

Manufacturers expected contribution to the progressive control of Foot-and-Mouth Disease in South Asia

Materials and Methods

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Foot and Mouth Disease Middle East situation Summary of Answers to the Questionnaire Beirut, Lebanon, 7 9 April 2009

FMD vaccination and postvaccination. guidelines. Samia Metwally (FAO) Animal Production and Health Division FAO of the United Nations Rome, Italy

Dr Ghazi Yehia OIE Regional Representative for the Middle East

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE (CVMP)

Foot and Mouth Disease vaccination is effective: Quantification of FMD transmission with and without vaccination

Lelystad, The Netherlands

REPORT ON THE SITUATION OF FMD IN TURKEY

This CRP is proposed for five years with three RCM. To apply, please see our website for directions:

COMMITTEE FOR MEDICINAL PRODUCTS FOR VETERINARY USE

SCIENTIFIC DISCUSSION

FOOT AND MOUTH DISEASE DIAGNOSTICS: REQUIREMENTS FOR DEMONSTRATION OF FREEDOM FROM INFECTION

COMPARISON OF DIFFERENT ELISA METHODS FOR THE DETECTION OF ANTIBODIES AGAINST FOOT-AND-MOUTH DISEASE VIRUS (FMDV) TYPE O

The global control of FMD; challenges and opportunities

FMD in Libya. Dr. Abdunaser Dayhum National Center of Animal Health Libya

Chapter 6. Foot and mouth disease virus transmission during the incubation period of the disease in piglets, lambs, calves, and dairy cows

Foot and mouth disease control strategies in North Africa and the Middle East the current

Vaccination against Bluetongue

Appendix 72 Using NSP ELISA (Chekit-FMD-3ABC Bommeli-Intervet) as a Tool for FMDV Serosurveillance in Bulgaria Abstract: Introduction

High potency vaccines induce protection against heterologous challenge with FMD virus

Engineering Foot-and-Mouth Disease Virus with Improved Properties for the Development of Effective Vaccine Introduction: Materials and methods:

Chapter 5b. RT-PCR tests on tonsils of foot and mouth disease virus infected piglets at least four weeks after initial challenge

1. Engineering Foot-and-Mouth Disease Viruses with Improved

INTERNATIONAL WORKSHOP BLUETONGUE VACCINES 19 February 2013, Strasbourg, France ABSTRACTS

A solid-phase competition ELISA for measuring antibody to foot-and-mouth disease virus

Points to consider in the prevention, control and eradication of FMD Dr. Paul Sutmoller* and Dr. Simon Barteling**

FMD VACCINE AND VACCINATION. Ahmad Al-Majali Dean, Faculty of Vet Medicine JUST Jordan

Foot and Mouth Disease Vaccine Research and Development in India

Using chloroform as a preservative for trivalent foot and mouth disease vaccine in comparison to thiomersal

Longevity of protection in cattle following vaccination with emergency FMD vaccines from the UK strategic reserve

Progress report on the EUFMD supported actions in FMD Control in the Republic of Azerbaijan. Leos Celeda, Chairman EUFMD

Is my vaccination programme working? Vaccine effectiveness: measuring vaccine protection in the field

FMD Carrier state and role of carrier buffalo as source of transboundary spread in Southeast Asia and Eastern Asia Satya Parida

PROGRESS REPORT FOR TURKEY ON FMD SITUATION AND CONTROL MEASURES

INTERNATIONAL STANDARDS FOR VACCINE BANKS

Foot and Mouth Disease (FMD) and FBS

Myanmar Disease Surveillance & Monitoring

Toward the control of Foot-and-Mouth disease in East Asia

COMMISSION REGULATION (EU)

DR G.H. GERDES & REF. LABORATORY STAFF ONDERSTEPOORT

7th Regional FMD West Eurasia Roadmap Meeting The incursion of new strain of FMD virus on the territory of Armenia

Experimental evaluation of foot-and-mouth disease vaccines for emergency use in ruminants and pigs: a review

Questionnaire results

PCP Stage 1 focus: To gain an understanding of the epidemiology of FMD in the country and develop a risk-based approach to reduce the impact of FMD

Requirements of the Terrestrial Code for FMD surveillance. Dr David Paton Dr Gideon Brückner

OIE endorsement of FMD control programs and recognition of diseasefree. Gideon Brűckner President: OIE Scientific Commission for Animal Diseases

REGIONAL REFERENCE LABORATORY FOR FMD IN SOUTH EAST ASIA DEPARTMENT OF LIVESTOCK DEVELOPMENT PAKCHONG, NAKHONRATCHASIMA, THAILAND

Republic of Kazakhstan

Member update on FMD Control and the Roadmap. Country Report - Mongolia

Self-declaration of the recovery of freedom from highly pathogenic avian influenza in poultry by the Netherlands

Adopted by CVMP 10 March Date for coming into effect 1 July Revised draft guideline agreed by Immunologicals Working Party 22 June 2017

Country Report on FMD in Uganda

Regional Status and FMD s Control Strategies in North Africa

Overview of WRL FMD. Historical perspective. Principal activities. FMD threats. Needs/prospects. David Paton

Foot and mouth disease vaccination and post-vaccination monitoring. Guidelines. Editors Samia Metwally Susanne Münstermann

Controlling Foot-and-Mouth Disease in the Netherlands (21 March to 22 April 2001)

Foot and mouth disease vaccination and post-vaccination monitoring. Guidelines. Editors Samia Metwally Susanne Münstermann

Vaccine matching. Reliability of foot-and-mouth disease r-values. determination

West Eurasia Regional Roadmap Meeting Country Presentation 2012

Paper on needs and support to be provided to North African countries, members of REMESA regarding the coordinated control of FMD

Draft Agreed by Immunologicals Working Party January Adoption by CVMP for release for consultation 12 March 2009

RVF Vaccination strategies, vaccine availability and quality control. Danny Goovaerts DVM

FMD CONTROL IN KYRGYZSTAN State Inspectorate for Veterinary and Phyto- Sanitary Security under the Government of the Kyrgyz Republic

Surveillance strategies for Foot and Mouth Disease to prove absence from disease and absence of viral circulation

Foot and Mouth Disease

WHEN FMD GOES WILD LINKING ECOLOGY, EPIDEMIOLOGY AND SURVEILLANCE. Sergei Khomenko, Tsviatko Alexandrov, Naci Bulut, Sinan Aktas, Keith Sumption

FMD Control Initiatives in Bangladesh

Verification of Efficacy of Donated FMD O Type Vaccines in Laos

ASEAN STANDARDS FOR ANIMAL VACCINES

Update to Iowa Foot and Mouth Disease (FMD) and Livestock Emergency Management Plans

FMD Vaccine Strain Selection

FMD - TURKEY. Yener ŞEKERCAN. Veterinary Officer General Directorate of Food and Control Ankara/TURKEY

Rotavec Corona Emulsion for injection for cattle. Introduction. Company name: MSD Animal Health. Address: Walton Manor. Walton. Milton Keynes MK7 7AJ

The New FMD Containment Zone Proposal and Vaccination. April 4, 2017, Pirenopolis, Brazil

Novel FMD vaccine research in China

Fare clic per modificare lo stile del titolo

Field study conducted in Tunisia to evaluate efficacy of an O-BFS vaccine

Lumpy skin disease (LSD) & Sheep Pox. State of play in the EU

PINOY PORCINE PRACTITIONERS, INC. Unit 201 Saint Rafael Suites, 941 San Rafael Street, Plainview, Mandaluyong City 1550 Philippines

EUROPEAN LIVESTOCK AND MEAT TRADING UNION / EUROPÄISCHE VIEH- UND FLEISCHHANDELSUNION

Agencia Española de Medicamentos y Productos Sanitarios C/Campezo 1, Edificio Madrid España (Reference Member State)

Key words: foot-and-mouth disease; single emulsion vaccine, saponin, immune response, emergency vaccines.

WEST EURASIA FMD LAB PHASE ACTIVITY PROPOSAL. A. Naci BULUT Head of the Diagnosis Department, Şap Institute

Scientific Opinion on sheep pox and goat pox - first part

Mission of the Community Veterinary Emergency Team to Bulgaria. (16-21 July 2018)

The Global control of FMD - Tools, ideas and ideals Erice, Italy October 2008

National Foot and mouth Disease Control and Eradication Plan in Thailand

OIE/FAO Global Conference on foot and mouth disease. The way towards global control. Paraguay: 24 to 26 June Draft Resolution version 8

ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS

Appendix 30. Preliminary results to evaluate cross-protection between O 1 Manisa and O 1 Campos in cattle

EPIDEMIOLOGICAL SITUATION. for S&GP, PPR andbt

Elements of the FMD control problem in Southern Africa: 2

landbouw, natuur en voedselkwaliteit Epidemiological report BTV 6 in the Netherlands

The Global control of FMD - Tools, ideas and ideals Erice, Italy October 2008

Transcription:

Appendix 3 Cedivac-FMD; Duration of Immunity in cattle, sheep and pigs. Paulus Selman *, Gilles Chénard and Aldo Dekker Animal Sciences Group, Wageningen UR, P.O. Box 65, 8 AB Lelystad, The Netherlands Central Institute for Animal Disease Control Lelystad (CIDC-Lelystad), Wageningen UR, P.O. Box 4, 83 AA Lelystad, The Netherlands * Corresponding Author Abstract: In this study, the FMD antibody profiles in cattle, sheep and pigs were investigated for a period of 6 months following the single administration of a vaccine dose corresponding with a potency of 6 PD 5. Monovalent double oil emulsion Cedivac-FMD vaccines containing either O Manisa, A Turkey 4/98 or Asia Shamir were used. For each serotype, two or three batches of vaccine were formulated. Each vaccine batch was administered to 5 cattle, 5 pigs and 5 sheep. Blood samples were collected at regular intervals for up to 6 months following vaccination. Antibody titers were determined using the virus neutralization test. Statistical analyses were done using an ANOVA for repeated measurements. For all FMD strains, the antibody titers increased rapidly in the first month. In the following months the antibody titers remained stable or still increased but at a much lower rate. For all FMD strains and for all species, antibody levels at 6 months were higher than at 4 weeks post vaccination. Although there were significant differences in the antibody profiles between the species for all FMD strains tested, the clinical relevance of this finding is probably limited. For each of the FMD strains tested, there were no significant differences between the antibody profiles raised by the various batches of Cedivac-FMD. The studies demonstrate that Cedivac-FMD DOE vaccines confer a duration of immunity of at least 6 months in cattle, sheep, and pigs. The data suggest that even beyond this period high levels of antibodies are maintained for O Manisa, A Turkey, and Asia Shamir. Introduction: The duration of immunity (DOI) is an important characteristic of the efficacy of a vaccine and should be supported by data of laboratory and field trials (). In the literature, surprisingly little data can be found on the DOI of regular or emergency FMD vaccinations. In FMD-endemic countries it is desirable to use FMD vaccines that provide as long a DOI as possible in order to avoid frequent re-vaccination. In the European Union, the DOI of FMD vaccines has become important since the vaccinate-to-live strategy was adopted after the massive FMD outbreaks round the turn of the century. Before that time, ring vaccinations were only used to prevent spreading of the disease from the source of contamination. Within weeks following the conformation of an outbreak and the subsequent emergency vaccinations, all animals, both infected and vaccinated, were killed. A DOI longer than those few weeks was not necessary. The new EU regulations permit vaccinated animals to be kept alive. After an outbreak, a region is only declared free of FMD after a period of 6 months without new FMD outbreaks. It is therefore important to know whether or not during that period re-vaccination of animals is necessary. In this study, antibody titers in cattle, pigs, and sheep, were measured during a six-month period following the single administration of monovalent Cedivac-FMD double oil emulsion vaccines containing 6 PD 5 of the FMD strains O Manisa, A Turkey 4/98, or Asia Shamir. Materials and Methods:.. Vaccines All vaccines administered were manufactured by the Animal Sciences Group, Lelystad, The Netherlands and contained inactivated, purified FMD antigens using a mineral oil as adjuvant in a double oil emulsion formulation. Batches of monovalent vaccines were formulated using antigens derived from FMD strains O Manisa (n = 3), A Turkey 4/98 (n = 3), and Asia Shamir (n = ). In previously conducted PD 5 experiments, the potency (PD 5 /ml) for each of the used formulations 5

had been assessed. Based on these data, and for each of the FMD serotypes, the volume corresponding with exactly 6 PD 5 was calculated and administered to each animal... Animals and husbandry All animals used in the experiments were conventionally bred and obtained from established commercial suppliers (Dumeco BV., Boxtel, The Netherlands and Topigs BV., Helvoirt, The Netherlands). were approximately 3 months of age and sheep and pigs were approximately months of age at the time of vaccination. All animals were housed in appropriate facilities of the Animal Sciences Group, Lelystad and were fed conventionally..3. Experiment design All animals received a volume of vaccine corresponding with exactly 6 PD 5. Representative strains of the FMD serotypes O, A and Asia were chosen and for each FMD strain, two or three batches of vaccine were formulated. Six PD 5 doses of each batch of vaccine were administered to 5 cattle, 5 pigs and 5 sheep. Blood samples were collected at regular intervals for up to 6 months following vaccination and the resulting serum samples were analyzed in the virus neutralization test (VNT). In analogy with European Pharmacopoeia requirements (3), the serological levels at 4 weeks post vaccination were considered to indicate acceptable levels of immunity. The differences between VNT titers of the species, batches, and time points were analysed using an ANOVA for Repeated Measurements and, if appropriate, followed by a Tukey-Kramer multiple comparison..4. Virus Neutralisation Test The virus neutralisation test (VNT) was performed according to OIE guidelines, chapter... Endpoint titers were expressed as the reciprocal of the final serum dilution (log ) that neutralized TCID 5 of FMD virus in 5% of the wells. Results: In all cases, the antibody titers increased rapidly in the first month. In the following months the antibody titers remained stable or still increased but at a much lower rate (Figures -3). For all FMD strains and for all species, antibody levels at 6 months were higher than at 4 weeks post vaccination. For all FMD strains, significant differences between antibody profiles of the various species were found (in all cases P <.). No significant differences were found between the VNT titers raised by the various Cedivac- FMD vaccine batches for each of the FMD strains (O Manisa: P =.7; A Turkey4/98: P =.7; Asia Shamir: P =.45). Discussion: The main objective of this study was to evaluate the duration of immunity in cattle, pigs, and sheep, following the single administration of monovalent Cedivac-FMD vaccines containing either O Manisa, A Turkey 4/98, or Asia Shamir-derived antigens. All individual animals received a dose which corresponded with a potency of 6 PD 5, a dose which is generally accepted as the minimal accepted potency for FMD emergency vaccines. The results of this study clearly demonstrate that at the end of the study period of six months, for all species and for all of the FMD strains tested, the antibody levels were higher than corresponding antibody levels at 4 weeks post vaccination. Since according to EU regulations (3), the antibody titers raised by a 6 PD 5 FMD vaccine at 3-4 weeks post vaccination are considered to provide a sufficient immunity in vaccinated animals, it can be concluded that the DOI of Cedivac-FMD vaccines is at least 6 months. The high levels of antibodies observed at 6 months post vaccination suggest that the DOI could extend beyond this period. The onset of immunity, both for the various FMD strains tested and the various species, were highly similar with the exception of titers in pigs vaccinated with Asia Shamir. Although the onset in pigs was slower, antibody titers reached levels comparable to those the other species in the following months. Also for the other FMD strains tested, significant differences were observed in the VNT titers between species. In the case of O Manisa and A Turkey 4/98, these differences most probably have little clinical relevance. For all three FMD strains, no significant difference in the VNT titers between vaccine batches was measured. This indicates a low batch-to-batch variability of Cedivac-FMD vaccines. 6

Conclusion: The Duration of Immunity for Cedivac-FMD vaccines is at least 6 months in cattle, pigs and sheep. In a separate study we have demonstrated that vaccination with Cedivac-FMD vaccines do not raise antibodies against the non-structural proteins of FMD viruses (4). The relatively long DOI and the marker vaccine capabilities make Cedivac-FMD vaccines excellent candidates for use in both emergency situations and FMD-endemic regions. References:. EMEA/CVMP/68/99-Final, Note for Guidance: Duration of Protection Achieved by Veterinary Vaccines.. EMEA/CVMP/775/-Final, Position Paper on Requirements for Vaccines Against Foot-and- Mouth Disease 3. European Pharmacopoeia 5., 5:63; Foot-and-mouth disease (ruminants) vaccine (inactivated). 4. Chenard, G., Orsel, K., Selman, P. et al.: Cedivac-FMD, a marker vaccine?; In: Session of the Research Group of the Standing Technical Committee of the European Commission for the control of Foot-and-Mouth Disease; Paphos, Cyprus, October 6. 7

Tables and Figures 3.5 3.5.5 4 8 6 4 Figure. VNT (mean + sem) after vaccination with 6 PD 5 of O Manisa. 3.5.5 4 8 6 4 Figure. VNT (mean + sem) after vaccination with 6 PD 5 of A Turkey 4/98. 8

3.5.5 4 8 6 4 Figure 3. VNT (mean + sem) after vaccination with 6 PD 5 of Asia Shamir. 9